Evidence map›Paper›PMID 31456528›Full record

ArticleCurrent radiopharmaceuticals2020

Preparation and Biological Evaluation of

Amir Jalali, Mona Haddad Zahmatkesh, Amir Reza Jalilian, Amir Taheri Borujeni, Behrouz Alirezapour

Abstract read
In one paragraph

Article in Current radiopharmaceuticals, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amir JalaliDepartment of Toxicology, School of Pharmacy and Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mona Haddad ZahmatkeshDepartment of Nuclear Pharmacy, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran.
Amir Reza JalilianDepartment of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna International Centre, Vienna, Austria.
Amir Taheri BorujeniDepartment of Toxicology, School of Pharmacy and Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Behrouz AlirezapourRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Hemiscorpius lepturus (H. lepturus) is a deadly scorpion species living in the southern Iran.

objectiveH. lepturus induces delayed toxicity symptoms and understanding the long term biodistribution/ biokinetic of the venom is of great interest in toxicology.

methodsA Ga-67 labeled venom was prepared using a DOTA -conjugated venom followed by radiolabeling using 67GaCl3 at 40°C for 90 min. The purification of the radiolabeled venom was performed using size exclusion-chromatography (radiochemical purity 71%). The radiolabeled venom was stable in the final solution in the presence of human serum at 37°C for 72 hours. The tissue distribution was studied in blood, heart, liver, spleen, muscle, brain, kidney, intestine and skin tissues at the intervals of 1, 4, 24, 48 and 72 hours using tissue counting and SPECT imaging.

resultsThe radiolabeled venom mixture obtained with an estimated molar activity of 0.52 MBq/μg. The main accumulation tissues during the first 72 hours were kidneys, blood, liver, intestines, stomach and skin, respectively. Therefore, it is likely that H. lepturus' clinical effects and renal toxicity are primary and caused by direct effects of the H. lepturus venom.

conclusionThe results have largely shown the direct clinical effects on the studied tissues during the 72-hour period and antivenom administration can strongly alleviate the toxicity effects as early as 72 hours in the management of the patients.

Indexed as

Gallium RadioisotopesRadiopharmaceuticalsTissue DistributionAnimalsHumansIranMaleMiceMice, Inbred BALB CModels, AnimalScorpionsScorpion VenomsTomography, Emission-Computed, Single-PhotonGallium-67Gallium RadioisotopesRadiopharmaceuticalsScorpion Venoms67Ga-DOTA-HLVgallium-67Hemiscorpius lepturusradiolabelingscorpion venomSPECT

Identifiers

PMID31456528
PMCPMC7527549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.